The Mission of the Yale Center for Molecular Discovery (YCMD) is to blend innovative research capabilities and practical experience to develop a nimble means to accelerate basic scientific concepts into innovative applications. YCMD works with investigators with breakthrough ideas and works with them to accelerate and broaden the potential for new grants, manuscripts and future partnerships. Our mission is accomplished using a mix of internal laboratory expertise with consultative services to provide customized solutions for the unique challenges of each project. YCMD seeks to synergize existing technologies and expertise in a manner that expands the quality and breadth of services to investigators in a cost-effective manner. Prominent services include the development of robust assays for high content and/or high-throughput screening. Complementing this, YCMD amassed the reagents and expertise to conduct screening campaigns with small molecule and/or siRNA libraries. These activities have been successfully utilized to facilitate the discovery and prosecution of new targets that are relevant to cancer. Recently, YCMDs impact increased by providing much-needed chemistry-based services, including ligand and structure based design, compound synthesis and analoging and natural product library generation. Beyond the discovery of novel targets and agents, YCMD works with Yale Cancer Center investigators to identify opportunities for synergistic combination of known antitumor agents. Each project is tailored to meet the specific needs of our customers. Key considerations for each project are the time, cost, and probability of meeting the investigator research goal. In partnership with a representative from each laboratory, we combine precise knowledge of the research field and specific handling considerations of experimental reagents. Barriers to new technology can be daunting, especially those involving sophisticated instrumentation;thus we streamline and direct the screening process for each project to maximize efficiency of all resources.

Public Health Relevance

The Yale Center for Molecular Discovery (YCMD) works with investigators with breakthrough ideas and works with them to accelerate and broaden the potential for new grants, manuscripts and future partnerships. YCMD's mission is accomplished using a mix of internal laboratory expertise with consultative services to provide customized solutions for the unique challenges of each project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755640
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$96,446
Indirect Cost
$38,521
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564

Showing the most recent 10 out of 675 publications